Empowering Cell Therapies
Revolutionizing cell therapy development and application at scale to improve patient access and enable individuals to take charge of their health.
Making Cell Therapies Accessible to Everyone
Cell therapies have the potential to cure diseases, but immune rejection limits access to only 20% of patients. ImmunoShield eliminates this barrier, expanding the market 5x and making breakthrough treatments available to millions.
-
The Problem
80% of patients are excluded from cell therapies due to dangerous immune suppression drugs.
-
Our Solution
Proprietary technology shields cells from immune rejection without compromising function.
-
Market Size
$18.3B cell therapy market growing at 18.7% annually, with allogeneic fastest at 27%.
-
Expert Team
15+ years of cell therapy expertise with proven track record in commercialization.
Investment Opportunity
Seeking pre-seed investment to complete large animal studies and position for strategic pharma partnerships. Backed by $1.8M NIH SBIR award and partnerships with leading institutions.
- 5.5xMarket expansion potential
- $1.8MNIH funding secured
- TRL 4Technology readiness
-
80%
Patients currently excluded
-
$18.3B
Cell therapy market size
-
27%
Annual growth rate
-
20+
Industry interviews